EFFPAC: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal - TCTMD

EFFPAC: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal  TCTMD

PARIS, France—Compared with plain balloon angioplasty (POBA), a paclitaxel-coated balloon results in better patency and less TLR at 24 months in ...



Comments

Post a Comment

Popular posts from this blog

Orchestra BioMed™ Announces FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon for Treatment of Below-the-Knee Peripheral Artery Disease - Vascular Disease Management

Orchestra BioMed™ Announces FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon for Treatment of Below-the-Knee Peripheral Artery Disease    Vascular Disease Management First and only non-coated sirolimus-eluting angioplasty balloon system to receive Breakthrough Device designation for below-the-knee disease; Follows ...
Read more